Suzanne Ildstad is Director at Talaris Therapeutics, Inc. (TALS). They have made 13 open-market trades across 1 company since 2022, most recently 2023-06-14.
CIK 0001845822
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 13 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| TALS | 3,784,334 | $102.9M |
Shares reported on the most recent Form 4, priced at the 2023-06-14 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| TALS | SELL | 2023-06-12 | 2023-06-14 | $2.55 | $112K | +22.2% | +23.8% | +8.1% |
| TALS | SELL | 2023-06-07 | 2023-06-09 | $2.43 | $685K | +7.1% | +24.2% | +11.1% |
| TALS | SELL | 2023-06-05 | 2023-06-07 | $2.53 | $149K | -5.2% | +26.4% | +14.4% |
| TALS | SELL | 2023-06-01 | 2023-06-05 | $2.53 | $80K | -5.3% | +16.4% | +9.2% |
| TALS | SELL | 2023-04-21 | 2023-04-25 | $2.35 | $35K | +11.8% | +1.9% | +13.7% |
| TALS | SELL | 2023-04-19 | 2023-04-21 | $2.30 | $266K | +14.8% | +16.4% | +25.8% |
| TALS | SELL | 2023-04-17 | 2023-04-19 | $2.14 | $639K | +28.2% | +29.5% | +36.4% |
| TALS | SELL | 2023-03-17 | 2023-03-20 | $2.06 | $21K | -5.8% | +15.8% | +24.7% |
| TALS | SELL | 2023-03-03 | 2023-03-07 | $2.06 | $14K | +5.0% | -10.6% | +31.2% |
| TALS | SELL | 2023-03-01 | 2023-03-02 | $2.05 | $59 | -4.0% | -8.0% | +32.5% |
| TALS | SELL | 2023-02-21 | 2023-02-23 | $2.05 | $7K | +4.2% | -6.8% | +42.4% |
| TALS | SELL | 2023-02-16 | 2023-02-21 | $2.05 | $13K | -1.0% | -13.4% | +40.6% |
| TALS | SELL | 2022-08-22 | 2022-08-23 | $2.80 | $1.5M | -9.1% | -25.7% | -61.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.